Naringin ameliorates doxorubicin-induced neurotoxicity In vitro and cognitive dysfunction In vivo

Objectives: The primary objective of the study was to study the neuroprotective potential of naringin (NAR) against doxorubicin (DOX)-induced neurotoxicity in vitro and DOX-induced cognitive deficits (chemobrain) in vivo. Materials and Methods: In vitro methods, viz., 3-[4,5dimethylthiazol-2-yl]-2,5...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pharmacognosy Magazine 2018-04, Vol.14 (55), p.197-207
Hauptverfasser: Ramalingayya, Grandhi, Nayak, Pawan, Shenoy, Rekha, Mallik, Sanchari, Gourishetti, Karthik, Hussain, Shalam, Rao, Chamallamudi, Nandakumar, Krishnadas
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 207
container_issue 55
container_start_page 197
container_title Pharmacognosy Magazine
container_volume 14
creator Ramalingayya, Grandhi
Nayak, Pawan
Shenoy, Rekha
Mallik, Sanchari
Gourishetti, Karthik
Hussain, Shalam
Rao, Chamallamudi
Nandakumar, Krishnadas
description Objectives: The primary objective of the study was to study the neuroprotective potential of naringin (NAR) against doxorubicin (DOX)-induced neurotoxicity in vitro and DOX-induced cognitive deficits (chemobrain) in vivo. Materials and Methods: In vitro methods, viz., 3-[4,5dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide assay, flow cytometry, acridine orange/ethidium bromide staining, and neuritogenic and reactive oxygen species (ROS) assays, assessed neuroprotective potential of NAR and its aglycone naringenin (NGN) in IMR-32 cells. Chemobrain was developed in Wistar rats on chronic administration of ten cycles of DOX, and episodic memory was assessed using novel object recognition task. Serum cortisol, locomotor activity, and hematological biochemical and histological analysis were carried out. Results: A protective effect of NAR or NGN was observed upon pretreatment with the respective compounds in IMR-32 cells challenged with DOX. Flow cytometry revealed that flavonoids reduced cell cycle changes produced by DOX. In addition, an increase in apoptosis, intracellular ROS generation, and inhibition of neurite growth was noticed in IMR-32 cells with DOX treatment, which was significantly prevented by NAR or NGN pretreatment. Interestingly, NAR (50 mg/kg, p.o.) significantly ameliorated episodic memory deficit associated with DOX without influencing locomotion, upon chronic treatment. NAR also prevented histological changes to major organs observed with DOX. Conclusion: NAR showed neuroprotective potential and may be used as an adjuvant therapy for amelioration of neurocognitive complications associated with chemotherapy in cancer survivors. Abbreviations used: CKL: Creatine kinase level; COX: Cyclooxygenase; DMEM: Dulbecco's modified eagle media; DOX: Doxorubicin; FBS: Fetal bovine serum; MTT: 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide; NAR: Naringin; NGN: Naringenin; NORT: Novel object recognition task; NOS: Nitric oxide synthase; QOL: Quality of life; RA: retinoic acid.
doi_str_mv 10.4103/pm.pm_364_17
format Article
fullrecord <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_2112130626</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A545381420</galeid><sourcerecordid>A545381420</sourcerecordid><originalsourceid>FETCH-LOGICAL-c330t-4362e7b592e97db0c35f1558f491eec5d4e331cd397a1864296b21c54734d3283</originalsourceid><addsrcrecordid>eNptkU1LAzEQhoMoWKs3f0DAq1vzuR_HUvwoFL3oOWSTbEnpJmuSLe2_N1pRBJnDDC_PzDDzAnCN0YxhRO-Gfjb0gpZM4OoETFBTlQVDJTn9qmmBSVOeg4sYNwjxGqNqAuSzDNatrYOyN1vrg0wmQu33PoytVdYV1ulRGQ2dGYNPfp_FdIBLB3c2BQ-l01D5tbPJ7gzUh9iNTiXr3RHZ-Utw1sltNFffeQreHu5fF0_F6uVxuZivCkUpSgWjJTFVyxtimkq3SFHeYc7rjjXYGMU1M5RipWlTSVyXLJ_SEqw4qyjTlNR0Cm6Oc4fg30cTk9j4Mbi8UhCMCab5EeUvtZZbI6zrfApS9TYqMeeM0xozgjI1-4fKoU1vlXems1n_03B7bFDBxxhMJ4ZgexkOAiPx6Y3Ixvx4Qz8AZGeCKg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2112130626</pqid></control><display><type>article</type><title>Naringin ameliorates doxorubicin-induced neurotoxicity In vitro and cognitive dysfunction In vivo</title><source>PubMed Central Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Ramalingayya, Grandhi ; Nayak, Pawan ; Shenoy, Rekha ; Mallik, Sanchari ; Gourishetti, Karthik ; Hussain, Shalam ; Rao, Chamallamudi ; Nandakumar, Krishnadas</creator><creatorcontrib>Ramalingayya, Grandhi ; Nayak, Pawan ; Shenoy, Rekha ; Mallik, Sanchari ; Gourishetti, Karthik ; Hussain, Shalam ; Rao, Chamallamudi ; Nandakumar, Krishnadas</creatorcontrib><description>Objectives: The primary objective of the study was to study the neuroprotective potential of naringin (NAR) against doxorubicin (DOX)-induced neurotoxicity in vitro and DOX-induced cognitive deficits (chemobrain) in vivo. Materials and Methods: In vitro methods, viz., 3-[4,5dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide assay, flow cytometry, acridine orange/ethidium bromide staining, and neuritogenic and reactive oxygen species (ROS) assays, assessed neuroprotective potential of NAR and its aglycone naringenin (NGN) in IMR-32 cells. Chemobrain was developed in Wistar rats on chronic administration of ten cycles of DOX, and episodic memory was assessed using novel object recognition task. Serum cortisol, locomotor activity, and hematological biochemical and histological analysis were carried out. Results: A protective effect of NAR or NGN was observed upon pretreatment with the respective compounds in IMR-32 cells challenged with DOX. Flow cytometry revealed that flavonoids reduced cell cycle changes produced by DOX. In addition, an increase in apoptosis, intracellular ROS generation, and inhibition of neurite growth was noticed in IMR-32 cells with DOX treatment, which was significantly prevented by NAR or NGN pretreatment. Interestingly, NAR (50 mg/kg, p.o.) significantly ameliorated episodic memory deficit associated with DOX without influencing locomotion, upon chronic treatment. NAR also prevented histological changes to major organs observed with DOX. Conclusion: NAR showed neuroprotective potential and may be used as an adjuvant therapy for amelioration of neurocognitive complications associated with chemotherapy in cancer survivors. Abbreviations used: CKL: Creatine kinase level; COX: Cyclooxygenase; DMEM: Dulbecco's modified eagle media; DOX: Doxorubicin; FBS: Fetal bovine serum; MTT: 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide; NAR: Naringin; NGN: Naringenin; NORT: Novel object recognition task; NOS: Nitric oxide synthase; QOL: Quality of life; RA: retinoic acid.</description><identifier>ISSN: 0973-1296</identifier><identifier>EISSN: 0976-4062</identifier><identifier>DOI: 10.4103/pm.pm_364_17</identifier><language>eng</language><publisher>London: Medknow Publications and Media Pvt. Ltd</publisher><subject>Animal cognition ; Breast cancer ; Cancer therapies ; Care and treatment ; Cell cycle ; Chemo brain ; Chemotherapy ; Cognitive ability ; Complications and side effects ; Cytokines ; Doxorubicin ; Drug dosages ; Drug-induced dyskinesia ; Flavonoids ; Gene expression ; Health aspects ; Memory ; Metabolism ; Metabolites ; Neurotoxicity ; Pharmacognosy ; Pharmacological research ; Physiological aspects ; Reactive oxygen species ; Risk factors ; Rodents ; Studies</subject><ispartof>Pharmacognosy Magazine, 2018-04, Vol.14 (55), p.197-207</ispartof><rights>COPYRIGHT 2018 Medknow Publications and Media Pvt. Ltd.</rights><rights>2018. This work is published under https://creativecommons.org/licenses/by-nc-sa/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c330t-4362e7b592e97db0c35f1558f491eec5d4e331cd397a1864296b21c54734d3283</citedby><cites>FETCH-LOGICAL-c330t-4362e7b592e97db0c35f1558f491eec5d4e331cd397a1864296b21c54734d3283</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Ramalingayya, Grandhi</creatorcontrib><creatorcontrib>Nayak, Pawan</creatorcontrib><creatorcontrib>Shenoy, Rekha</creatorcontrib><creatorcontrib>Mallik, Sanchari</creatorcontrib><creatorcontrib>Gourishetti, Karthik</creatorcontrib><creatorcontrib>Hussain, Shalam</creatorcontrib><creatorcontrib>Rao, Chamallamudi</creatorcontrib><creatorcontrib>Nandakumar, Krishnadas</creatorcontrib><title>Naringin ameliorates doxorubicin-induced neurotoxicity In vitro and cognitive dysfunction In vivo</title><title>Pharmacognosy Magazine</title><description>Objectives: The primary objective of the study was to study the neuroprotective potential of naringin (NAR) against doxorubicin (DOX)-induced neurotoxicity in vitro and DOX-induced cognitive deficits (chemobrain) in vivo. Materials and Methods: In vitro methods, viz., 3-[4,5dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide assay, flow cytometry, acridine orange/ethidium bromide staining, and neuritogenic and reactive oxygen species (ROS) assays, assessed neuroprotective potential of NAR and its aglycone naringenin (NGN) in IMR-32 cells. Chemobrain was developed in Wistar rats on chronic administration of ten cycles of DOX, and episodic memory was assessed using novel object recognition task. Serum cortisol, locomotor activity, and hematological biochemical and histological analysis were carried out. Results: A protective effect of NAR or NGN was observed upon pretreatment with the respective compounds in IMR-32 cells challenged with DOX. Flow cytometry revealed that flavonoids reduced cell cycle changes produced by DOX. In addition, an increase in apoptosis, intracellular ROS generation, and inhibition of neurite growth was noticed in IMR-32 cells with DOX treatment, which was significantly prevented by NAR or NGN pretreatment. Interestingly, NAR (50 mg/kg, p.o.) significantly ameliorated episodic memory deficit associated with DOX without influencing locomotion, upon chronic treatment. NAR also prevented histological changes to major organs observed with DOX. Conclusion: NAR showed neuroprotective potential and may be used as an adjuvant therapy for amelioration of neurocognitive complications associated with chemotherapy in cancer survivors. Abbreviations used: CKL: Creatine kinase level; COX: Cyclooxygenase; DMEM: Dulbecco's modified eagle media; DOX: Doxorubicin; FBS: Fetal bovine serum; MTT: 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide; NAR: Naringin; NGN: Naringenin; NORT: Novel object recognition task; NOS: Nitric oxide synthase; QOL: Quality of life; RA: retinoic acid.</description><subject>Animal cognition</subject><subject>Breast cancer</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>Cell cycle</subject><subject>Chemo brain</subject><subject>Chemotherapy</subject><subject>Cognitive ability</subject><subject>Complications and side effects</subject><subject>Cytokines</subject><subject>Doxorubicin</subject><subject>Drug dosages</subject><subject>Drug-induced dyskinesia</subject><subject>Flavonoids</subject><subject>Gene expression</subject><subject>Health aspects</subject><subject>Memory</subject><subject>Metabolism</subject><subject>Metabolites</subject><subject>Neurotoxicity</subject><subject>Pharmacognosy</subject><subject>Pharmacological research</subject><subject>Physiological aspects</subject><subject>Reactive oxygen species</subject><subject>Risk factors</subject><subject>Rodents</subject><subject>Studies</subject><issn>0973-1296</issn><issn>0976-4062</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkU1LAzEQhoMoWKs3f0DAq1vzuR_HUvwoFL3oOWSTbEnpJmuSLe2_N1pRBJnDDC_PzDDzAnCN0YxhRO-Gfjb0gpZM4OoETFBTlQVDJTn9qmmBSVOeg4sYNwjxGqNqAuSzDNatrYOyN1vrg0wmQu33PoytVdYV1ulRGQ2dGYNPfp_FdIBLB3c2BQ-l01D5tbPJ7gzUh9iNTiXr3RHZ-Utw1sltNFffeQreHu5fF0_F6uVxuZivCkUpSgWjJTFVyxtimkq3SFHeYc7rjjXYGMU1M5RipWlTSVyXLJ_SEqw4qyjTlNR0Cm6Oc4fg30cTk9j4Mbi8UhCMCab5EeUvtZZbI6zrfApS9TYqMeeM0xozgjI1-4fKoU1vlXems1n_03B7bFDBxxhMJ4ZgexkOAiPx6Y3Ixvx4Qz8AZGeCKg</recordid><startdate>20180401</startdate><enddate>20180401</enddate><creator>Ramalingayya, Grandhi</creator><creator>Nayak, Pawan</creator><creator>Shenoy, Rekha</creator><creator>Mallik, Sanchari</creator><creator>Gourishetti, Karthik</creator><creator>Hussain, Shalam</creator><creator>Rao, Chamallamudi</creator><creator>Nandakumar, Krishnadas</creator><general>Medknow Publications and Media Pvt. Ltd</general><general>Sage Publications Ltd</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>20180401</creationdate><title>Naringin ameliorates doxorubicin-induced neurotoxicity In vitro and cognitive dysfunction In vivo</title><author>Ramalingayya, Grandhi ; Nayak, Pawan ; Shenoy, Rekha ; Mallik, Sanchari ; Gourishetti, Karthik ; Hussain, Shalam ; Rao, Chamallamudi ; Nandakumar, Krishnadas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c330t-4362e7b592e97db0c35f1558f491eec5d4e331cd397a1864296b21c54734d3283</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Animal cognition</topic><topic>Breast cancer</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>Cell cycle</topic><topic>Chemo brain</topic><topic>Chemotherapy</topic><topic>Cognitive ability</topic><topic>Complications and side effects</topic><topic>Cytokines</topic><topic>Doxorubicin</topic><topic>Drug dosages</topic><topic>Drug-induced dyskinesia</topic><topic>Flavonoids</topic><topic>Gene expression</topic><topic>Health aspects</topic><topic>Memory</topic><topic>Metabolism</topic><topic>Metabolites</topic><topic>Neurotoxicity</topic><topic>Pharmacognosy</topic><topic>Pharmacological research</topic><topic>Physiological aspects</topic><topic>Reactive oxygen species</topic><topic>Risk factors</topic><topic>Rodents</topic><topic>Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ramalingayya, Grandhi</creatorcontrib><creatorcontrib>Nayak, Pawan</creatorcontrib><creatorcontrib>Shenoy, Rekha</creatorcontrib><creatorcontrib>Mallik, Sanchari</creatorcontrib><creatorcontrib>Gourishetti, Karthik</creatorcontrib><creatorcontrib>Hussain, Shalam</creatorcontrib><creatorcontrib>Rao, Chamallamudi</creatorcontrib><creatorcontrib>Nandakumar, Krishnadas</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Pharmacognosy Magazine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ramalingayya, Grandhi</au><au>Nayak, Pawan</au><au>Shenoy, Rekha</au><au>Mallik, Sanchari</au><au>Gourishetti, Karthik</au><au>Hussain, Shalam</au><au>Rao, Chamallamudi</au><au>Nandakumar, Krishnadas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Naringin ameliorates doxorubicin-induced neurotoxicity In vitro and cognitive dysfunction In vivo</atitle><jtitle>Pharmacognosy Magazine</jtitle><date>2018-04-01</date><risdate>2018</risdate><volume>14</volume><issue>55</issue><spage>197</spage><epage>207</epage><pages>197-207</pages><issn>0973-1296</issn><eissn>0976-4062</eissn><abstract>Objectives: The primary objective of the study was to study the neuroprotective potential of naringin (NAR) against doxorubicin (DOX)-induced neurotoxicity in vitro and DOX-induced cognitive deficits (chemobrain) in vivo. Materials and Methods: In vitro methods, viz., 3-[4,5dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide assay, flow cytometry, acridine orange/ethidium bromide staining, and neuritogenic and reactive oxygen species (ROS) assays, assessed neuroprotective potential of NAR and its aglycone naringenin (NGN) in IMR-32 cells. Chemobrain was developed in Wistar rats on chronic administration of ten cycles of DOX, and episodic memory was assessed using novel object recognition task. Serum cortisol, locomotor activity, and hematological biochemical and histological analysis were carried out. Results: A protective effect of NAR or NGN was observed upon pretreatment with the respective compounds in IMR-32 cells challenged with DOX. Flow cytometry revealed that flavonoids reduced cell cycle changes produced by DOX. In addition, an increase in apoptosis, intracellular ROS generation, and inhibition of neurite growth was noticed in IMR-32 cells with DOX treatment, which was significantly prevented by NAR or NGN pretreatment. Interestingly, NAR (50 mg/kg, p.o.) significantly ameliorated episodic memory deficit associated with DOX without influencing locomotion, upon chronic treatment. NAR also prevented histological changes to major organs observed with DOX. Conclusion: NAR showed neuroprotective potential and may be used as an adjuvant therapy for amelioration of neurocognitive complications associated with chemotherapy in cancer survivors. Abbreviations used: CKL: Creatine kinase level; COX: Cyclooxygenase; DMEM: Dulbecco's modified eagle media; DOX: Doxorubicin; FBS: Fetal bovine serum; MTT: 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide; NAR: Naringin; NGN: Naringenin; NORT: Novel object recognition task; NOS: Nitric oxide synthase; QOL: Quality of life; RA: retinoic acid.</abstract><cop>London</cop><pub>Medknow Publications and Media Pvt. Ltd</pub><doi>10.4103/pm.pm_364_17</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0973-1296
ispartof Pharmacognosy Magazine, 2018-04, Vol.14 (55), p.197-207
issn 0973-1296
0976-4062
language eng
recordid cdi_proquest_journals_2112130626
source PubMed Central Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Animal cognition
Breast cancer
Cancer therapies
Care and treatment
Cell cycle
Chemo brain
Chemotherapy
Cognitive ability
Complications and side effects
Cytokines
Doxorubicin
Drug dosages
Drug-induced dyskinesia
Flavonoids
Gene expression
Health aspects
Memory
Metabolism
Metabolites
Neurotoxicity
Pharmacognosy
Pharmacological research
Physiological aspects
Reactive oxygen species
Risk factors
Rodents
Studies
title Naringin ameliorates doxorubicin-induced neurotoxicity In vitro and cognitive dysfunction In vivo
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T23%3A23%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Naringin%20ameliorates%20doxorubicin-induced%20neurotoxicity%20In%20vitro%20and%20cognitive%20dysfunction%20In%20vivo&rft.jtitle=Pharmacognosy%20Magazine&rft.au=Ramalingayya,%20Grandhi&rft.date=2018-04-01&rft.volume=14&rft.issue=55&rft.spage=197&rft.epage=207&rft.pages=197-207&rft.issn=0973-1296&rft.eissn=0976-4062&rft_id=info:doi/10.4103/pm.pm_364_17&rft_dat=%3Cgale_proqu%3EA545381420%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2112130626&rft_id=info:pmid/&rft_galeid=A545381420&rfr_iscdi=true